US 12024718
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted A61KA61K2039/5158A61K35/17
Quick answer
US patent 12024718 (Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy) held by Iovance Biotherapeutics, Inc. expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/5158, A61K35/17, A61K39/0011